These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 8587635)
1. Can aluminium-containing antacid produce dementia? Jobst K; Nagy J Nephron; 1995; 71(4):473. PubMed ID: 8587635 [No Abstract] [Full Text] [Related]
2. The kinetics of aluminium-containing antacid absorption in man. Nagy E; Jobst K Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):119-21. PubMed ID: 8031961 [TBL] [Abstract][Full Text] [Related]
3. The kinetics of initial gastrointestinal absorption of an aluminium-containing antacid (Tisacid) in patients with various stages of chronic renal insufficiency. Sárszegi Z; Nagy J; Jobst K Nephrol Dial Transplant; 1997 Feb; 12(2):372-3. PubMed ID: 9132675 [No Abstract] [Full Text] [Related]
4. Serum aluminium levels of intensive care patients treated with two different antacids for prevention of stress ulceration. Rauch H; Fleischer F; Böhrer H; Jürs G; Wilhelm M; Krier C Intensive Care Med; 1989; 15(2):84-6. PubMed ID: 2785545 [TBL] [Abstract][Full Text] [Related]
5. Hyperaluminaemia in critically ill patients: role of antacid therapy and impaired renal function. Ittel TH; Gladziwa U; Mück W; Sieberth HG Eur J Clin Invest; 1991 Feb; 21(1):96-102. PubMed ID: 1907560 [TBL] [Abstract][Full Text] [Related]
7. Differences in plasma and tissue aluminum concentrations due to different aluminum-containing drugs in patients with renal insufficiency and with normal renal function. Winterberg B; Bertram H; Rolf N; Roedig M; Kisters K; Remmers S; Spieker C; Zumkley H J Trace Elem Electrolytes Health Dis; 1987 Dec; 1(2):69-72. PubMed ID: 2856571 [TBL] [Abstract][Full Text] [Related]
8. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. Krishna R; East L; Larson P; Valiathan C; Butterfield K; Teng Y; Hernandez-Illas M J Pharm Pharmacol; 2016 Nov; 68(11):1359-1365. PubMed ID: 27671833 [TBL] [Abstract][Full Text] [Related]
9. [Aluminum and magnesium burden of dialysis patients using antacids. A comparative study]. Eichhorn M Fortschr Med; 1989 Aug; 107(23):502-6. PubMed ID: 2670719 [TBL] [Abstract][Full Text] [Related]
10. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin. Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343 [TBL] [Abstract][Full Text] [Related]
12. Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. Nassr N; Lahu G; Hünnemeyer A; von Richter O; Knoerzer D; Reutter F; Zech K; Hermann R J Clin Pharmacol; 2007 May; 47(5):660-6. PubMed ID: 17374735 [No Abstract] [Full Text] [Related]
13. A new form of Rickets during infancy: phosphate depletion-induced osteopenia due to antacid ingestion. Chesney RW Arch Pediatr Adolesc Med; 1998 Dec; 152(12):1168-9. PubMed ID: 9856423 [No Abstract] [Full Text] [Related]
14. Hypermagnesemia and intestinal perforation following antacid administration in a premature infant. Brand JM; Greer FR Pediatrics; 1990 Jan; 85(1):121-4. PubMed ID: 2296480 [No Abstract] [Full Text] [Related]